- Similarities between COVID-19 and systemic sclerosis early vasculopathy: A “viral” challenge for future research in scleroderma
- Immune system response, hyperinflammation and repurposing antirheumatic drugs
- Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19)
- JAK1 2 inhibitor ruxolitinib for severe COVID-19
- Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis
- Lung ultrasound in COVID-19 pneumonia
- The clinical challenge of interstitial lung
- Arthritis after SARSCoV-2 infection
- Challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress
- Response to: ‘Correspondence on ‘Systemic sclerosis and the COVID-19 pandemic
- Chilblains are a cutaneous manifestation of COVID-19 infection
- COVID-19 and systemic sclerosis clinicopathological
- Combined lung and cardiac ultrasound in COVID-related acute respiratory distress syndrome
- COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab
- The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET
